Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - TripCo Outstanding Awards (Details)

v3.20.2
Stock-Based Compensation - TripCo Outstanding Awards (Details) - 2019 Plan
$ / shares in Units, shares in Thousands, $ in Millions
9 Months Ended
Sep. 30, 2020
USD ($)
item
$ / shares
shares
Additional disclosures  
Unvested value not yet recognized | $ $ 373
Weighted average period the unrecognized compensation cost will be recognized 2 years 8 months 12 days
Amount of share reserve 2,300
Stock Options | Series A  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding beginning balance 717
Granted 77
Forfeited/Cancelled (271)
Outstanding ending balance 523
Options exercisable 294
WAEP  
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares $ 13.65
Weighted average exercise price, options granted (in dollars per share) | $ / shares 2.72
Weighted average exercise price, options forfeited/cancelled (in dollars per share) | $ / shares 14.11
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares 11.80
Weighted average exercise price, options exercisable (in dollars per share) | $ / shares $ 16.55
Weighted average remaining contractual term outstanding 4 years 9 months 18 days
Weighted average remaining contractual term exercisable 3 years 7 months 6 days
Stock Options | Series B  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding beginning balance 1,824
Outstanding ending balance 1,824
Options exercisable 1,824
WAEP  
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares $ 27.63
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares 27.63
Weighted average exercise price, options exercisable (in dollars per share) | $ / shares $ 27.63
Weighted average remaining contractual term outstanding 4 years 2 months 12 days
Weighted average remaining contractual term exercisable 4 years 2 months 12 days
Outstanding, aggregate intrinsic value | $ $ 15
Exercisable, aggregate intrinsic value | $ $ 15
Performance Based RSUs | Series B | CEO  
Additional disclosures  
RSUs granted 242
Weighted average grant date fair value, RSUs and MSUs granted (in dollars per share) | $ / shares $ 3.08
Vesting period 1 year
Time Based RSUs | Series B | CEO  
Additional disclosures  
RSUs granted 30
Weighted average grant date fair value, RSUs and MSUs granted (in dollars per share) | $ / shares $ 4.76
Percentage of base salary 50.00%
Number of quarters | item 3
Percentage of base salary to be waived 50.00%